WO1995030440A1 - Composition antifongique stockable dans la keratine pour usage externe - Google Patents
Composition antifongique stockable dans la keratine pour usage externe Download PDFInfo
- Publication number
- WO1995030440A1 WO1995030440A1 PCT/JP1995/000773 JP9500773W WO9530440A1 WO 1995030440 A1 WO1995030440 A1 WO 1995030440A1 JP 9500773 W JP9500773 W JP 9500773W WO 9530440 A1 WO9530440 A1 WO 9530440A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- solution
- antifungal
- keratin
- gel
- Prior art date
Links
- 239000012871 anti-fungal composition Substances 0.000 title claims abstract description 7
- LVYLCBNXHHHPSB-UHFFFAOYSA-N 2-hydroxyethyl salicylate Chemical compound OCCOC(=O)C1=CC=CC=C1O LVYLCBNXHHHPSB-UHFFFAOYSA-N 0.000 claims abstract description 40
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims abstract description 40
- 229940121375 antifungal agent Drugs 0.000 claims abstract description 37
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 claims abstract description 32
- 229960003338 crotamiton Drugs 0.000 claims abstract description 32
- 229960002389 glycol salicylate Drugs 0.000 claims abstract description 20
- 229960001047 methyl salicylate Drugs 0.000 claims abstract description 20
- 239000007788 liquid Substances 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 12
- 230000000843 anti-fungal effect Effects 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 60
- 239000006071 cream Substances 0.000 claims description 38
- 239000003429 antifungal agent Substances 0.000 claims description 25
- OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 claims description 22
- 229960002206 bifonazole Drugs 0.000 claims description 22
- 239000002674 ointment Substances 0.000 claims description 21
- 229940041616 menthol Drugs 0.000 claims description 15
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 12
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 claims description 11
- 229960000699 terbinafine hydrochloride Drugs 0.000 claims description 11
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 8
- 229960004125 ketoconazole Drugs 0.000 claims description 8
- 229950010757 neticonazole Drugs 0.000 claims description 7
- VWOIKFDZQQLJBJ-DTQAZKPQSA-N neticonazole Chemical compound CCCCCOC1=CC=CC=C1\C(=C/SC)N1C=NC=C1 VWOIKFDZQQLJBJ-DTQAZKPQSA-N 0.000 claims description 7
- -1 lanconazole Chemical compound 0.000 claims description 5
- MQHLMHIZUIDKOO-AYHJJNSGSA-N amorolfine Chemical compound C1=CC(C(C)(C)CC)=CC=C1CC(C)CN1C[C@@H](C)O[C@@H](C)C1 MQHLMHIZUIDKOO-AYHJJNSGSA-N 0.000 claims description 4
- 229960005279 amorolfine hydrochloride Drugs 0.000 claims description 4
- SUMAWDZJEIQACJ-UHFFFAOYSA-N 2-methylpyridine-4-carbaldehyde Chemical compound CC1=CC(C=O)=CC=N1 SUMAWDZJEIQACJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960003273 butenafine hydrochloride Drugs 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims 1
- 102000011782 Keratins Human genes 0.000 abstract description 12
- 108010076876 Keratins Proteins 0.000 abstract description 12
- 235000014435 Mentha Nutrition 0.000 abstract 1
- 241001072983 Mentha Species 0.000 abstract 1
- 230000000149 penetrating effect Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 63
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000000499 gel Substances 0.000 description 45
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 34
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 33
- 238000002156 mixing Methods 0.000 description 28
- 239000008213 purified water Substances 0.000 description 24
- 239000003921 oil Substances 0.000 description 22
- 235000019198 oils Nutrition 0.000 description 22
- 239000007864 aqueous solution Substances 0.000 description 21
- 239000011928 denatured alcohol Substances 0.000 description 20
- 238000003756 stirring Methods 0.000 description 20
- 229920002125 Sokalan® Polymers 0.000 description 18
- 229940058015 1,3-butylene glycol Drugs 0.000 description 17
- 239000002585 base Substances 0.000 description 17
- 235000019437 butane-1,3-diol Nutrition 0.000 description 17
- 239000004615 ingredient Substances 0.000 description 17
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 15
- 238000010438 heat treatment Methods 0.000 description 15
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 14
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 10
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 9
- 210000000434 stratum corneum Anatomy 0.000 description 9
- 229920002675 Polyoxyl Polymers 0.000 description 8
- HBTAOSGHCXUEKI-UHFFFAOYSA-N 4-chloro-n,n-dimethyl-3-nitrobenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 HBTAOSGHCXUEKI-UHFFFAOYSA-N 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- 229940031578 diisopropyl adipate Drugs 0.000 description 7
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 7
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 7
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 7
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 7
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 6
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 6
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 6
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 5
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 5
- 229940043276 diisopropanolamine Drugs 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 235000019271 petrolatum Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000003871 white petrolatum Substances 0.000 description 5
- 229920000298 Cellophane Polymers 0.000 description 4
- ZRTQSJFIDWNVJW-WYMLVPIESA-N Lanoconazole Chemical compound ClC1=CC=CC=C1C(CS\1)SC/1=C(\C#N)N1C=NC=C1 ZRTQSJFIDWNVJW-WYMLVPIESA-N 0.000 description 4
- 229920002884 Laureth 4 Polymers 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 229950010163 lanoconazole Drugs 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- ZDQWESQEGGJUCH-UHFFFAOYSA-N Diisopropyl adipate Chemical compound CC(C)OC(=O)CCCCC(=O)OC(C)C ZDQWESQEGGJUCH-UHFFFAOYSA-N 0.000 description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 201000009862 superficial mycosis Diseases 0.000 description 3
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 2
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 description 2
- LJOQGZACKSYWCH-WZBLMQSHSA-N hydroquinine Chemical compound C1=C(OC)C=C2C([C@@H](O)[C@@H]3C[C@@H]4CCN3C[C@@H]4CC)=CC=NC2=C1 LJOQGZACKSYWCH-WZBLMQSHSA-N 0.000 description 2
- 229960004251 hydroquinine Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229940060184 oil ingredients Drugs 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229940116351 sebacate Drugs 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 2
- 229940012831 stearyl alcohol Drugs 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- LGURYBCSJPXHTF-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)ethyl benzoate Chemical compound ClC1=CC(Cl)=CC=C1OCCOC(=O)C1=CC=CC=C1 LGURYBCSJPXHTF-UHFFFAOYSA-N 0.000 description 1
- DLGBEGBHXSAQOC-UHFFFAOYSA-M 2-carboxy-4-methylphenolate Chemical compound CC1=CC=C(O)C(C([O-])=O)=C1 DLGBEGBHXSAQOC-UHFFFAOYSA-M 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- JYZLSYFPFQTNNO-UHFFFAOYSA-N 2-octyldecan-1-ol Chemical compound CCCCCCCCC(CO)CCCCCCCC JYZLSYFPFQTNNO-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- DSEKYWAQQVUQTP-UHFFFAOYSA-N Cerin Natural products CC12CCC3(C)C4CC(C)(C)CCC4(C)CCC3(C)C2CCC2(C)C1CC(O)C(=O)C2C DSEKYWAQQVUQTP-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910001854 alkali hydroxide Inorganic materials 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- GNVMUORYQLCPJZ-UHFFFAOYSA-N carbamothioic s-acid Chemical compound NC(S)=O GNVMUORYQLCPJZ-UHFFFAOYSA-N 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- BJHIKXHVCXFQLS-OTWZMJIISA-N keto-L-sorbose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-OTWZMJIISA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
Definitions
- the present invention relates to an external antifungal composition containing an antifungal agent having a high keratin affinity as an active ingredient. More specifically, it is selected from methyl salicylate, glycol salicylate, crotamiton, and hatsune oil or menthol for the purpose of further improving the keratin permeability of the antifungal agent having a high keratophilicity to further improve the storage property.
- the present invention relates to a stratum corneum-storing antifungal external composition containing one or more liquid oil substances.
- the fungi In superficial mycosis, the fungi mainly penetrate into the stratum corneum of the skin and multiply, so that the antimicrobial agent does not exert excellent medicinal properties against superficial mycosis. In addition to having fungal activity, it is necessary to achieve long-term maintenance at a high drug concentration level in the epidermal stratum corneum, which is the site of infection.
- antifungal agents with high keratophilicity have been developed to achieve this purpose, and antifungal external preparations that exert a clinical effect on superficial mycosis with a single application have been put to practical use.
- antifungal agent penetrates into the stratum corneum of the epidermis, and a formulation for that purpose is required.
- these antifungal agents having a high keratophilicity are extremely poorly soluble, and it is difficult to increase the solubility in a base material. It is not a keratin-retentive antifungal external preparation that maximizes affinity.
- the present inventors have proposed to enhance the keratin permeability and retention of an antifungal agent having a high keratin affinity. As a result of repeated examinations for the purpose of formulating, it is formulated with an external base as a mixture of methyl salicylate, glycol salicylate, crotamiton, and one or more liquid oils selected from hatsune oil or menthol. However, they have found that it is possible to enhance the keratin permeability and retention of an antifungal agent having a high keratophilicity, and have completed the present invention.
- an external preparation containing an antifungal agent having a high keratophilicity as an active ingredient methyl salicylate, glycol salicylate, crotami, which have high solubility in the antifungal agent and have good keratin permeability.
- the external use composition of the present invention has been found to promote the penetration of the antifungal agent into the stratum corneum of the epidermis by using together with ton, heart-strength oil or menthol, and to further aid in the binding and immobilization of the constituents of the stratum corneum of the epidermis.
- the method of blending one or more liquid oily substances selected from methyl salicylate, glycol salicylate, crotamiton, and heart-strength oil or menthol in a product requires a keratin affinity to a normal external base It is also possible to mix the above liquid oils such as methyl salicylate at the same time when compounding a high antifungal agent, More preferably, the antifungal agent having high keratophilicity is dissolved in advance using various solvents, and at this time, the liquid oily substance such as methyl salicylate or the like in an amount sufficient to dissolve the antifungal agent so that complete dissolution can be achieved.
- the antifungal agent can achieve complete dissolution with the above liquid oil such as methyl salicylate.
- a method is employed in which the liquid oily substance is dissolved alone without using any other solvent, and then mixed with an external base to prepare.
- the above-mentioned liquid oily substance such as methyl salicylate used in the present invention is expected to have an auxiliary effect as an external preparation itself, and further enhances the effect of the antifungal component as a main component.
- Preferred antifungal agents having a high keratophilicity used in the present invention include benzylamine antifungal agents such as butenafin hydrochloride, imidazole antifungal agents such as bifonazole, neticonazole hydrochloride, ketoconazole and lanconazole, and terbinafine hydrochloride. And the like, morpholine antifungals such as amorolfine hydrochloride, and thiocarbamic acid antifungals such as riranaphthalate.
- the amount of the compound is 0.5 to 3. 0% by weight, preferably 1.0 to 2.0% by weight.
- the amount of the liquid oily substance selected from methyl salicylate, glycol salicylate, crotamiton, and coconut oil or menthol to be added to the keratin-retaining antifungal composition for external use of the present invention is determined in advance by using an antifungal agent having a high keratin affinity.
- an antifungal agent having a high keratin affinity In the process of dissolution using various solvents, sufficient amount to dissolve the antifungal agent with high keratophilicity to achieve complete dissolution, or sufficient amount to dissolve alone if no other solvent is used Is sufficient, and it is generally 1.0 to 10% by weight based on the total amount of the composition.
- dissolving the antifungal agent with high keratophilicity is generally 1.0 to 10% by weight based on the total amount of the composition.
- the keratin-retaining antifungal composition for external use of the present invention may be used in any of the usual dosage forms used for skin external preparations, that is, any of ointments, creams, gels, gel creams, lotions, solutions and the like. Shapes can also be used.
- an antifungal agent having a high keratophilicity of the active ingredient and various liquid bases in addition to the liquid oily substance can be molded by a conventional method, as described above.
- liquid oily substances such as methyl salicylate or other solvents (eg, lower alcohols such as ethanol; 1,3-butylene glycol, polyethylene glycol)
- solvents eg, lower alcohols such as ethanol; 1,3-butylene glycol, polyethylene glycol
- Polyhydric alcohols such as ethanol 400
- liquid oil substances such as isopropyl myristate, diisopropyl adipate, and octyldodecanol
- surfactants such as lauromacrogol and polyoxyl stearate 40. It is preferable to dissolve the solution, add the solution to an external base, and mix and formulate the mixture by a conventional method.
- carboxyvinyl polymer When molded as a gel, carboxyvinyl polymer, water-soluble base materials (eg, alkali hydroxide, alkanolamines, etc.), hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinyl alcohol, polyvinyl alcohol Gel bases such as pyrrolidone, purified water, lower alcohols, polyhydric alcohols and polyethylene glycol can be added.
- an emulsifier preferably a nonionic surfactant
- a liquid oily substance eg, liquid paraffin, isopropyl myristate, 2-hydroxyoctyl
- Dodecanol etc.
- lower alcohols such as ethanol and isopropanol, glycerin, propylene glycol,
- Polyhydric alcohols such as 1,3-butylene glycol and purified water can be added.
- antioxidant compounds usually contained in skin external preparations
- Preservatives, preservatives, preservatives, humectants, chelating agents, and other additives may be appropriately blended, and the preparation conditions for ordinary skin external preparations are also appropriately applied.
- An ointment having the following composition is prepared.
- An ointment having the following composition is prepared.
- Total amount 100.0 g A solution obtained by heating ketoconazole to crotamiton and glycol salicylate at a temperature of about 70 to 80 ° C. is added to plastibase, and the mixture is sufficiently stirred and kneaded to obtain an ointment.
- An ointment having the following composition is prepared.
- An ointment having the following composition is prepared.
- a total of 100.0 g of amorolfine hydrochloride was added to crotamiton, methyl salicylate, disopropyl adipate, 2% aqueous sodium hydroxide solution and lipophilic glycerol monooleate at a temperature of about 70 to 80 ° C, and plastibase was added. Stir and homogenize to obtain a cream.
- a gel having the following composition is prepared.
- a 4% aqueous solution of carboxyvinyl polymer is added to a mixture in which hydroxypropyl methylcellulose is uniformly dispersed in a part of denatured alcohol, and the mixture is stirred.Diisopropanolamine is added, and the mixture is stirred until it becomes uniform. A base is prepared, and the above-mentioned bifonazole-containing solution is added thereto and uniformly stirred to obtain a gel.
- a gel having the following composition is prepared.
- a total amount of 100.0 g Terbinafine hydrochloride is thoroughly stirred and dissolved in kutamitamin, a part of denatured alcohol, polyethylene glycol 400.
- a 4% aqueous solution of carboxyvinyl polymer is added to a mixture in which hydroxypropylmethylcellulose is uniformly dispersed in a part of the modified alcohol, and the mixture is stirred.Diisopropanolamine is added, and the mixture is stirred until uniform.
- To prepare a gel base add the above-mentioned terbinafine hydrochloride-containing solution and uniformly stir to obtain a gel base
- a gel having the following composition is prepared.
- Bifonazole 1.0 Monomenthol 3.0 Denatured alcohol 64.0 Hydroxypropyl methylcellulose 0. ⁇ 1,3-Butylene glycol 5.0 4% Carboxyvinyl polymer aqueous solution 25.0 Diisopropanolamine 1.5 Total amount 100.0 g Bifonazole is thoroughly stirred and dissolved in menthol, a part of denatured alcohol, 1,3-butylene glycol.
- a 4% aqueous solution of carboxyvinyl polymer is added to a mixture in which hydroxypropyl methylcellulose is uniformly dispersed in a part of denatured alcohol, and the mixture is stirred.Diisopropanolamine is added, and the mixture is stirred until uniform. A gel base is prepared, and the above-mentioned bifonazole-containing liquid is added thereto and uniformly stirred to obtain a gel.
- a gel cream having the following composition is prepared.
- 100.0 g bifonazole is treated with crotamiton, power oil, octyldodecanol, Nosutearin glyceryl and monostearate polyethylene glycol (45E.0.)
- c is dissolved in about 70 to 80 C warming to 2% aqueous solution Natoriumu aqueous 4% carboxy vinyl polymer solution, 1, 3-butylene Add glycol and purified water and stir to form a uniform gel, then heat to about 70-80 ° C.
- the above-mentioned heated drug solution is added to this, emulsified, and uniformly mixed to obtain a gel cream.
- a gel cream having the following composition is prepared.
- ketoconazole A total of 100.0 g of ketoconazole is dissolved in glycol salicylate, crotamiton, hatsune oil, diisopropyl adipate, glyceryl monostearate and polyoxyl monostearate 40 by heating to about 70-80 ° C.
- a 4% aqueous solution of carboxyvinyl polymer was added to a 2% aqueous solution of sodium hydroxide, Add 3-butylene glycol and purified water, stir to form a uniform gel, and heat to about 70-80 ° C.
- the above-mentioned heated drug solution is added to this, emulsified, and uniformly mixed to obtain a gel cream.
- Ketoconazo monophosphate 2.0 Diisopropyl adipate 15.0 Glycerin monostearate 2.0 Polyoxyl monostearate 40 2.0 1,3-butylene glycol 5.0 4% Carboxyvinyl polymer aqueous solution 25.0 2% Sodium hydroxide aqueous solution 10.0 Purification Water 39.0
- a gel cream having the following composition is prepared.
- Dissolve terbinafine hydrochloride in crotamiton, isopropyl myristate, lauromacrogol, and 2% sodium hydroxide aqueous solution by heating to about 70-80 ° C.
- add the remaining 2% aqueous sodium hydroxide solution, 1,3-butylene glycol and purified water to the 4% carboxyvinyl polymer aqueous solution stir to form a uniform gel, and then heat to about 70 to 80 ° C .
- the above-mentioned heated drug solution is added to this, emulsified and uniformly mixed to obtain a gel cream.
- a solution having the following composition is prepared.
- the total amount of 100.0 ml bifonazole is dissolved in heart-strength oil by heating to about 70-80 ° C. Add polyethylene glycol 400 and stir to make uniform, then make the total amount 10 O 1 and filter to obtain a solution.
- a solution having the following composition is prepared.
- Bifonazole 1.0 Crotamiton 5.0 Polyethylene glycol 400 10.0 Purified water 20.0 Denatured alcohol A total of 1000.0 ml bifonazole is dissolved in crotamiton and polyethylene glycol 400 by heating to about 70-80 ° C. Purified water was added, after a stirring uniformly added to denatured alcohol to make a total volume of 100 ml, to give a solution agent was filtered t
- Example 20 A solution having the same composition as that of Example 20 except that crotamiton was omitted was prepared in the same manner as in Example 20.
- the gel cream of Example 16 (referred to as gel cream A), the gel cream of Control 1 (referred to as gel cream B), the solution of Example 20 (referred to as solution A), and the control 2
- the solution (hereinafter referred to as solution B) was tested for keratin permeability as described below.
- test material was applied to the inner part of the upper arm of a human in a 5 X ⁇ cm area at a dose of 10 ml or 10 g, respectively, allowed to stand for 6 hours, and then 70% aqueous ethanol solution was applied. The sample remaining on the coated surface was wiped off with soaked absorbent cotton. Next, a cellophane tape was applied to the skin surface at the application site, and the stratum corneum was peeled off after pressure bonding. The detachment operation using the cellophane tape was repeated 10 times with a new cellophane tape at all times to completely separate the stratum corneum. Next, the cellophane tape was collected and extracted with ethanol, and the contents of bifonazole and ketoconazole (antifungal active components in each sample) in the stratum corneum were measured by high performance liquid chromatography.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002166388A CA2166388C (en) | 1994-05-06 | 1995-04-19 | Antifungal composition for external use retentive in stratum corneum |
DK95916014T DK0715856T3 (da) | 1994-05-06 | 1995-04-19 | Antifungalt præparat som kan oplagres i keratinlaget, til ekstern anvendelse |
US08/578,606 US6017920A (en) | 1994-05-06 | 1995-04-19 | Antifungal composition for external use being retentive in stratum corneum |
EP95916014A EP0715856B1 (en) | 1994-05-06 | 1995-04-19 | Keratin-storable antifungal composition for external use |
DE69535570T DE69535570T2 (de) | 1994-05-06 | 1995-04-19 | Antimykotische Zusammensetzung zur äusserlichen Anwendung, die im Stratum Corneum retentiv ist |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/94243 | 1994-05-06 | ||
JP9424394 | 1994-05-06 | ||
JP6/307521 | 1994-12-12 | ||
JP06307521A JP3081766B2 (ja) | 1994-05-06 | 1994-12-12 | 角質貯留型抗真菌外用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995030440A1 true WO1995030440A1 (fr) | 1995-11-16 |
Family
ID=26435510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/000773 WO1995030440A1 (fr) | 1994-05-06 | 1995-04-19 | Composition antifongique stockable dans la keratine pour usage externe |
Country Status (10)
Country | Link |
---|---|
US (1) | US6017920A (ja) |
EP (1) | EP0715856B1 (ja) |
JP (1) | JP3081766B2 (ja) |
AT (1) | ATE370747T1 (ja) |
CA (1) | CA2166388C (ja) |
DE (1) | DE69535570T2 (ja) |
DK (1) | DK0715856T3 (ja) |
ES (1) | ES2293640T3 (ja) |
PT (1) | PT715856E (ja) |
WO (1) | WO1995030440A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007102241A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
WO2007102242A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
WO2007102243A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
US8513296B2 (en) | 2007-09-05 | 2013-08-20 | Pola Pharma Inc. | Pharmaceutical composition |
US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US9050271B2 (en) | 2009-04-09 | 2015-06-09 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US9480678B2 (en) | 2007-09-05 | 2016-11-01 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
US9968591B2 (en) | 2007-09-05 | 2018-05-15 | Pola Pharma Inc. | Antifungal composition |
US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4814414B2 (ja) * | 2000-05-26 | 2011-11-16 | 大正製薬株式会社 | 抗真菌液剤組成物 |
US7244703B2 (en) * | 2001-06-22 | 2007-07-17 | Bentley Pharmaceuticals, Inc. | Pharmaceutical compositions and methods for peptide treatment |
GB0118300D0 (en) * | 2001-07-26 | 2001-09-19 | Cortendo Ab | Formulations |
WO2003080052A1 (en) * | 2002-03-25 | 2003-10-02 | Council Of Scientific And Industrial Research | A use of treatment for fungal infections with a synergistic formulation of antifungal agents |
JP4963776B2 (ja) * | 2002-03-08 | 2012-06-27 | 第一三共ヘルスケア株式会社 | 抗真菌活性増強型組成物及び抗真菌活性増強方法 |
DE10224087A1 (de) * | 2002-05-31 | 2003-12-11 | Symrise Gmbh & Co Kg | Kompaktiertes Menthol |
JP4081312B2 (ja) * | 2002-06-28 | 2008-04-23 | 佐藤製薬株式会社 | 外用抗真菌剤 |
AU2003262769A1 (en) * | 2002-08-20 | 2004-03-11 | Pinnell, Doren M | Methods for treating fungal infections |
JP2004083439A (ja) * | 2002-08-23 | 2004-03-18 | Ss Pharmaceut Co Ltd | 爪用抗真菌外用剤 |
EP1637132B1 (en) * | 2003-06-25 | 2010-10-06 | Hisamitsu Pharmaceutical Co., Inc. | External preparation for athlete´s foot treatment |
CN100393314C (zh) * | 2003-09-22 | 2008-06-11 | 北京德众万全药物技术开发有限公司 | 一种利拉萘酯凝胶组合物及其制备方法 |
DK1706128T3 (da) | 2003-12-08 | 2010-10-04 | Cpex Pharmaceuticals Inc | Farmaceutiske sammensætninger og fremgangsmåder til insulin-behandling |
WO2005082334A1 (ja) * | 2004-02-27 | 2005-09-09 | Hisamitsu Pharmaceutical Co., Inc. | 徐放性クリーム剤 |
JP4559753B2 (ja) * | 2004-02-27 | 2010-10-13 | 久光製薬株式会社 | 皮膚外用クリーム剤 |
US7740875B2 (en) * | 2004-10-08 | 2010-06-22 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060078580A1 (en) | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
EP1708049B1 (de) | 2005-03-31 | 2019-05-08 | Richemont International S.A. | Mondphasenanzeigemechanismus |
JP2007084496A (ja) * | 2005-09-22 | 2007-04-05 | Nippon Nohyaku Co Ltd | 抗真菌剤組成物 |
JP5061518B2 (ja) * | 2006-07-12 | 2012-10-31 | 大正製薬株式会社 | アモロルフィン含有o/wエマルション組成物 |
US20080146672A1 (en) * | 2006-12-08 | 2008-06-19 | Denton Marcia Marye | Topical Eutectic Anesthetic Composition for Oral or Dermal Tissue |
US20080153122A1 (en) * | 2006-12-21 | 2008-06-26 | Susan Beth Cantor | Method and system for enhancing self-treatment of onychomycosis |
JP5319950B2 (ja) | 2008-04-08 | 2013-10-16 | 帝國製薬株式会社 | 塩酸ブテナフィン含有水性貼付剤 |
CN102186341B (zh) | 2008-10-20 | 2013-12-25 | 荷兰联合利华有限公司 | 抗菌组合物 |
CN102395274B (zh) | 2009-02-13 | 2014-03-12 | 托派卡医药股份有限公司 | 抗真菌制剂 |
WO2011036048A1 (en) | 2009-09-24 | 2011-03-31 | Unilever Nv | Disinfecting agent comprising eugenol, terpineol and thymol |
JP2011173823A (ja) * | 2010-02-24 | 2011-09-08 | Hisamitsu Pharmaceut Co Inc | ゲル製剤 |
CN102933201B (zh) | 2010-06-11 | 2015-12-16 | 宝丽制药股份有限公司 | 抗真菌药物组合物 |
BR112013013085B1 (pt) | 2010-12-07 | 2018-02-14 | Unilever N.V. | Composição de cuidados orais, enxaguante bucal, creme dental, dentífrico, método para desinfetar a cavidade oral e uso de uma composição |
JP2012144449A (ja) * | 2011-01-07 | 2012-08-02 | Nippon Nohyaku Co Ltd | ルリコナゾールの皮膚浸透性を向上させる配合処方 |
WO2013064360A2 (en) | 2011-11-03 | 2013-05-10 | Unilever N.V. | A personal cleaning composition |
JP6016085B2 (ja) * | 2012-07-13 | 2016-10-26 | ダイヤ製薬株式会社 | 抗真菌外用組成物及び抗真菌外用組成物の適用方法 |
JP5460797B1 (ja) | 2012-09-14 | 2014-04-02 | 株式会社ポーラファルマ | アミド誘導体及び安定性指標としてのその使用 |
WO2014042231A1 (en) | 2012-09-14 | 2014-03-20 | Pola Pharma Inc. | Crystal and pharmaceutical preparation containing the same crystal |
CN104619704B (zh) | 2012-09-14 | 2017-12-05 | 宝丽制药股份有限公司 | 表面自由能用于分化评价晶体的用途,基于表面自由能作为指标评价的晶体,以及通过包含所述晶体制备的药物组合物 |
US9199977B2 (en) | 2012-09-14 | 2015-12-01 | Pola Pharma Inc. | Crystal having crystal habits and pharmaceutical composition obtained by processing the crystal |
JP5662495B2 (ja) * | 2013-02-08 | 2015-01-28 | 株式会社ポーラファルマ | 可溶化剤形の医薬組成物 |
JP6067399B2 (ja) * | 2013-02-08 | 2017-01-25 | 株式会社ポーラファルマ | 医薬組成物 |
JP5589110B1 (ja) | 2013-03-08 | 2014-09-10 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
JP5680161B1 (ja) | 2013-09-06 | 2015-03-04 | 株式会社ポーラファルマ | 晶癖を有する結晶及び該結晶を有効成分として含有する医薬組成物 |
JP5587488B1 (ja) | 2013-12-12 | 2014-09-10 | 株式会社ポーラファルマ | ルリコナゾールを含有する製剤の評価方法及び指標物質 |
JP6634703B2 (ja) * | 2014-06-10 | 2020-01-22 | 大正製薬株式会社 | 外用組成物 |
KR101690765B1 (ko) * | 2015-04-17 | 2016-12-28 | 동아제약 주식회사 | 항진균성 활성물질을 포함하는 경피 제제 |
CN104825388A (zh) * | 2015-04-20 | 2015-08-12 | 陈亚春 | 一种联苯苄唑溶液及其制备方法 |
KR20190067510A (ko) * | 2017-12-07 | 2019-06-17 | 한미약품 주식회사 | 테르비나핀을 포함하는 외용제 조성물 및 그 제조방법 |
CN110063934B (zh) * | 2018-01-22 | 2021-08-06 | 洛阳惠中兽药有限公司 | 一种治疗宠物真菌感染的利拉萘酯外用溶液及其制备方法 |
JP7399954B2 (ja) * | 2018-05-30 | 2023-12-18 | エヴィデルム・インスティテュート・アーベー | ウイルス及び真菌により引き起こされる皮膚障害及び爪障害の局所治療用の低刺激性組成物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6061518A (ja) * | 1983-09-14 | 1985-04-09 | Hisamitsu Pharmaceut Co Inc | ゲル状外用組成物 |
JPH02292219A (ja) * | 1989-05-08 | 1990-12-03 | Hoyu Co Ltd | 液状真菌症治療剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5815909A (ja) * | 1981-07-22 | 1983-01-29 | Toko Yakuhin Kogyo Kk | 抗真菌外用剤 |
US4636520A (en) * | 1984-07-16 | 1987-01-13 | Fujisawa Pharmaceutical Co., Ltd. | Antifungal composition employing pyrrolnitrin in combination with an imidazole compound |
JPH02264723A (ja) * | 1989-04-06 | 1990-10-29 | Taisho Pharmaceut Co Ltd | 抗真菌剤 |
-
1994
- 1994-12-12 JP JP06307521A patent/JP3081766B2/ja not_active Expired - Lifetime
-
1995
- 1995-04-19 DK DK95916014T patent/DK0715856T3/da active
- 1995-04-19 EP EP95916014A patent/EP0715856B1/en not_active Expired - Lifetime
- 1995-04-19 AT AT95916014T patent/ATE370747T1/de active
- 1995-04-19 DE DE69535570T patent/DE69535570T2/de not_active Expired - Lifetime
- 1995-04-19 PT PT95916014T patent/PT715856E/pt unknown
- 1995-04-19 CA CA002166388A patent/CA2166388C/en not_active Expired - Fee Related
- 1995-04-19 ES ES95916014T patent/ES2293640T3/es not_active Expired - Lifetime
- 1995-04-19 US US08/578,606 patent/US6017920A/en not_active Expired - Lifetime
- 1995-04-19 WO PCT/JP1995/000773 patent/WO1995030440A1/ja active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6061518A (ja) * | 1983-09-14 | 1985-04-09 | Hisamitsu Pharmaceut Co Inc | ゲル状外用組成物 |
JPH02292219A (ja) * | 1989-05-08 | 1990-12-03 | Hoyu Co Ltd | 液状真菌症治療剤 |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8349882B2 (en) | 2006-03-08 | 2013-01-08 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
WO2007102241A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
WO2007102243A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
JPWO2007102242A1 (ja) * | 2006-03-08 | 2009-07-23 | 日本農薬株式会社 | 外用の医薬組成物 |
US8058303B2 (en) | 2006-03-08 | 2011-11-15 | Nihon Nohyaku Co, Ltd | Pharmaceutical composition for external use |
US8268876B2 (en) | 2006-03-08 | 2012-09-18 | Nihon Nohyaku Co., Ltd. | Pharmaceutical composition for external use |
WO2007102242A1 (ja) * | 2006-03-08 | 2007-09-13 | Nihon Nohyaku Co., Ltd. | 外用の医薬組成物 |
JP5160409B2 (ja) * | 2006-03-08 | 2013-03-13 | 日本農薬株式会社 | 外用の医薬組成物 |
US8513296B2 (en) | 2007-09-05 | 2013-08-20 | Pola Pharma Inc. | Pharmaceutical composition |
US9480678B2 (en) | 2007-09-05 | 2016-11-01 | Pola Pharma Inc. | Antifungal pharmaceutical composition |
US9968591B2 (en) | 2007-09-05 | 2018-05-15 | Pola Pharma Inc. | Antifungal composition |
US9050271B2 (en) | 2009-04-09 | 2015-06-09 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US10130610B2 (en) | 2009-04-09 | 2018-11-20 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
US8952044B2 (en) | 2009-08-25 | 2015-02-10 | Pola Pharma Inc. | Antimycotic pharmaceutical composition |
Also Published As
Publication number | Publication date |
---|---|
DE69535570D1 (de) | 2007-10-04 |
ATE370747T1 (de) | 2007-09-15 |
JPH0820527A (ja) | 1996-01-23 |
ES2293640T3 (es) | 2008-03-16 |
DE69535570T2 (de) | 2008-01-03 |
PT715856E (pt) | 2007-11-27 |
EP0715856B1 (en) | 2007-08-22 |
EP0715856A1 (en) | 1996-06-12 |
JP3081766B2 (ja) | 2000-08-28 |
CA2166388C (en) | 2008-06-17 |
EP0715856A4 (en) | 1997-09-17 |
CA2166388A1 (en) | 1995-11-16 |
US6017920A (en) | 2000-01-25 |
DK0715856T3 (da) | 2007-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995030440A1 (fr) | Composition antifongique stockable dans la keratine pour usage externe | |
JP5290582B2 (ja) | 爪用医薬組成物 | |
WO1993023083A1 (en) | Anhydrous formulations for administering lipophilic agents | |
WO1988006041A1 (en) | Percutaneous absorption promoter and dermatologic preparation for external use | |
JPS6061518A (ja) | ゲル状外用組成物 | |
JP4195178B2 (ja) | 消炎鎮痛外用剤 | |
WO2002062336A1 (en) | Antifungal remedy formulation for external application | |
JPH05105628A (ja) | 外用消炎鎮痛剤 | |
JPH057370B2 (ja) | ||
JP3608209B2 (ja) | クロタミトン配合外用剤 | |
JP5125122B2 (ja) | アダパレン含有外用剤組成物 | |
JP4835411B2 (ja) | アダパレン含有外用剤組成物 | |
JP5061984B2 (ja) | アダパレン含有外用剤組成物 | |
WO1999001137A1 (fr) | Preparation percutanee contenant de l'hydrochlorure d'azelastine, presentant une bonne absorbabilite percutanee et une action d'irritation de la peau reduite | |
JPH0899889A (ja) | アトピー性皮膚炎治療剤 | |
EP0232830A1 (en) | A composition for the extemporary preparation of formulations for topical applications for pharmaceutical and cosmetic use | |
JPH02204413A (ja) | 抗真菌外用製剤 | |
WO1993024129A1 (en) | Composition for treating acne vulgaris | |
JP5109383B2 (ja) | アダパレン含有外用剤組成物 | |
JP5670008B2 (ja) | アダパレン含有外用剤組成物 | |
JP5109382B2 (ja) | アダパレン含有外用剤組成物 | |
JPH0228571B2 (ja) | ||
JPH111433A (ja) | トルナフテ−ト含有液剤 | |
JPS63208536A (ja) | 経皮吸収促進剤及びこれを含有する皮膚外用製剤 | |
JPH03148218A (ja) | コルヒチン含有外用剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2166388 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995916014 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08578606 Country of ref document: US |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1995916014 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995916014 Country of ref document: EP |